PRKAA2 and lung adenocarcinoma: EGFR signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma and EGFR-TKIs such as erlotinib and gefitinib are reported to drive energetic stress thus activate the AMPK pathway in EGFR (del19) lung tumors (Makinoshima et al., 2014; Momcilovic et al., 2017; Whang et al., 2016).